Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Key Information
Due Date: December 20, 2024
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: $581,371
Funding Type: Grant
Match Required: No
Contact Info:
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
This specific Funding Opportunity Announcement (FOA) is focused on inviting R33 applications that already have significant feasibility gaps for the enabling technology or transformative platform addressed with the help of preliminary data. However, these technologies and platforms still need further development and decisive validation to foster their demonstration, utilisation, and adoption downstream.
Ideal applications should present the potential to expedite and/or revolutionise areas such as early detection, screening, model development, clinical diagnosis, treatment, control, prevention, or epidemiology of HLBS-related diseases and disorders. Applications centered on the usage of existing technologies where the uniqueness lies in the biological or clinical target/question being addressed are not appropriate for this call and will not be considered.
This FOA is part of the broader NHLBI Catalyze program, aimed at progressing projects to the stage where they are eligible for inclusion in the NHLBI Catalyze Product Definition or Preclinical Funding Opportunity Announcements.
Key Dates
Open Date: January 24, 2022
Application Due Date: December 20, 2024
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses